Adaptimmune Therapeutics PLC’s (ADAP) Buy Rating Reiterated at SunTrust Banks, Inc.

SunTrust Banks, Inc. reiterated their buy rating on shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) in a report issued on Friday. SunTrust Banks, Inc. currently has a $10.00 target price on the biotechnology company’s stock.

Several other equities research analysts have also recently issued reports on ADAP. BidaskClub raised shares of Adaptimmune Therapeutics PLC from a sell rating to a hold rating in a research note on Sunday, July 16th. Zacks Investment Research cut shares of Adaptimmune Therapeutics PLC from a buy rating to a hold rating in a research note on Monday, July 17th. ValuEngine raised shares of Adaptimmune Therapeutics PLC from a strong sell rating to a sell rating in a research note on Thursday, July 20th. Leerink Swann reaffirmed an outperform rating and set a $15.00 target price on shares of Adaptimmune Therapeutics PLC in a research note on Friday, September 8th. Finally, TheStreet raised shares of Adaptimmune Therapeutics PLC from a d rating to a c rating in a research note on Thursday, November 2nd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company. The company has a consensus rating of Hold and an average price target of $11.58.

Shares of Adaptimmune Therapeutics PLC (ADAP) opened at $8.10 on Friday. Adaptimmune Therapeutics PLC has a one year low of $3.76 and a one year high of $9.29.

TRADEMARK VIOLATION NOTICE: This story was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://ledgergazette.com/2017/11/13/adaptimmune-therapeutics-plcs-adap-buy-rating-reiterated-at-suntrust-banks-inc.html.

Institutional investors and hedge funds have recently made changes to their positions in the business. KCG Holdings Inc. acquired a new stake in Adaptimmune Therapeutics PLC during the 1st quarter worth $133,000. OxFORD Asset Management LLP acquired a new stake in Adaptimmune Therapeutics PLC during the 2nd quarter worth $156,000. Paloma Partners Management Co acquired a new stake in Adaptimmune Therapeutics PLC during the 1st quarter worth $165,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Adaptimmune Therapeutics PLC during the 3rd quarter worth $199,000. Finally, Virtu KCG Holdings LLC raised its holdings in shares of Adaptimmune Therapeutics PLC by 108.0% during the 2nd quarter. Virtu KCG Holdings LLC now owns 50,279 shares of the biotechnology company’s stock worth $226,000 after acquiring an additional 26,105 shares during the period. 68.17% of the stock is currently owned by institutional investors.

About Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply